Proficio Capital Partners LLC Invests $535,000 in Insulet Corporation $PODD

Proficio Capital Partners LLC purchased a new position in Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, Holdings Channel reports. The fund purchased 3,517 shares of the medical instruments supplier’s stock, valued at approximately $535,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Headlands Technologies LLC grew its stake in Insulet by 2,041.5% in the 2nd quarter. Headlands Technologies LLC now owns 31,930 shares of the medical instruments supplier’s stock worth $4,861,000 after acquiring an additional 30,439 shares in the last quarter. Meiji Yasuda Life Insurance Co raised its stake in shares of Insulet by 46.1% during the second quarter. Meiji Yasuda Life Insurance Co now owns 10,429 shares of the medical instruments supplier’s stock valued at $1,588,000 after acquiring an additional 3,292 shares in the last quarter. New Mexico Educational Retirement Board raised its stake in shares of Insulet by 6.2% during the second quarter. New Mexico Educational Retirement Board now owns 3,400 shares of the medical instruments supplier’s stock valued at $518,000 after acquiring an additional 200 shares in the last quarter. Mufg Securities Americas Inc. boosted its holdings in shares of Insulet by 7.1% in the second quarter. Mufg Securities Americas Inc. now owns 2,086 shares of the medical instruments supplier’s stock valued at $318,000 after purchasing an additional 139 shares during the period. Finally, Van ECK Associates Corp boosted its holdings in shares of Insulet by 10.9% in the second quarter. Van ECK Associates Corp now owns 18,919 shares of the medical instruments supplier’s stock valued at $2,880,000 after purchasing an additional 1,858 shares during the period.

Analysts Set New Price Targets

Several research firms have commented on PODD. Benchmark reduced their price objective on Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft initiated coverage on Insulet in a report on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 target price for the company. Raymond James Financial reissued an “outperform” rating and set a $180.00 price target on shares of Insulet in a research report on Thursday, August 6th. Weiss Ratings lowered Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, June 24th. Finally, William Blair started coverage on Insulet in a report on Wednesday, May 20th. They issued an “outperform” rating for the company. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Insulet has a consensus rating of “Hold” and an average price target of $195.40.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $148.14 on Thursday. The company has a market capitalization of $10.27 billion, a price-to-earnings ratio of 27.69, a price-to-earnings-growth ratio of 1.17 and a beta of 1.08. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $154.73 and a 200 day moving average of $178.59.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. During the same quarter in the prior year, the business earned $1.17 earnings per share. Insulet’s revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts predict that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.